Giving US FDA the ability to easily clear the table of an accelerated approval drug that fails to confirm clinical benefit is proposed in a new white paper. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
